Immatics N.V.
IMTX
Jodie situation report
Immatics N.V.'s move is being confirmed by its market group.
No new filing conclusion is available. 21 of 21 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- At least 14 of 21 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as CBLL begins moving with the group.
Invalidation: The live read weakens if participation falls to 7 of 21 members or fewer.
Who this business touches
The relationships behind IMTX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
EDITEditas Medicine, Inc.partnerMar 9, 2026 ▾
“We are also party to a non-exclusive collaboration and licensing agreement with Immatics to combine gamma-delta T cell adoptive cell therapies and gene editing for the treatment of cancer.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
IMTX is currently a Participant in the organic co-movement group Oncology and Gastrointestinal Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.